Portal de Periódicos da CAPES

Association of anti‐ IL ‐12/23 biologic agents ustekinumab and briakinumab with major adverse cardiovascular events

2013; Wiley; Volume: 27; Issue: 12 Linguagem: Inglês

10.1111/jdv.12126

1468-3083

Thrasyvoulos Tzellos, Athanassios Kyrgidis, Anastasia Trigoni, Christos C. Zouboulis,

Psoriasis: Treatment and Pathogenesis

Journal of the European Academy of Dermatology and VenereologyVolume 27, Issue 12 p. 1586-1587 Letter to the Editor Association of anti-IL-12/23 biologic agents ustekinumab and briakinumab with major adverse cardiovascular events T. Tzellos, T. Tzellos Division of Evidenced-Based Dermatology, Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany Department of Pharmacology and Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this authorA. Kyrgidis, A. Kyrgidis Division of Evidenced-Based Dermatology, Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany Department of Pharmacology and Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this authorA. Trigoni, A. Trigoni State Clinic, Hospital for Skin and Venereal Diseases, Thessaloniki, GreeceSearch for more papers by this authorC.C. Zouboulis, Corresponding Author C.C. Zouboulis Division of Evidenced-Based Dermatology, Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany Correspondence: C.C. Zouboulis. E-mail:[email protected]Search for more papers by this author T. Tzellos, T. Tzellos Division of Evidenced-Based Dermatology, Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany Department of Pharmacology and Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this authorA. Kyrgidis, A. Kyrgidis Division of Evidenced-Based Dermatology, Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany Department of Pharmacology and Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this authorA. Trigoni, A. Trigoni State Clinic, Hospital for Skin and Venereal Diseases, Thessaloniki, GreeceSearch for more papers by this authorC.C. Zouboulis, Corresponding Author C.C. Zouboulis Division of Evidenced-Based Dermatology, Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany Correspondence: C.C. Zouboulis. E-mail:[email protected]Search for more papers by this author First published: 06 March 2013 https://doi.org/10.1111/jdv.12126Citations: 12Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Langley RG, Papp K, Gottlieb AB et al. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol 2012; doi: 10.1111/j.1468-3083.2012.04705.x. [Epub ahead of print]. 2Ryan C, Leonardi CL, Krueger JG et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011; 306: 864–871. 3Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol 2012; doi: 10.1111/j.1468-3083.2012.04500.x. [Epub ahead of print]. 4Tzellos T, Kyrgidis A, Toulis K. Biologic therapies for chronic plaque psoriasis and cardiovascular events. JAMA 2011; 306: 2095. 5Tzellos T, Kyrgidis A, Trigoni A, Zouboulis CC. Association of ustekinumab and briakinumab with major adverse cardiovascular events: an appraisal of meta-analyses and industry sponsored pooled analyses to date. Dermatoendocrinol 2012; 4:3: 1–4. 6Wu J, Poon KT, Channual JC, Shen A. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 2012; 148: 1244–1250. Citing Literature Volume27, Issue12December 2013Pages 1586-1587 ReferencesRelatedInformation